All Comparisons
MOTS-c vs Tesamorelin
Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.
MOTS-c: DTesamorelin: A
| Attribute | MOTS-c | Tesamorelin |
|---|---|---|
| Category | Metabolic / Mitochondrial | Growth Hormone Secretagogue |
| Evidence Rating | D — Preclinical | A — FDA Approved |
| Clinical Status | Research-only / No human clinical trials completed (Phase 1 of analog CB4211 only) | FDA-approved (Egrifta SV 2019, Egrifta WR March 2025) for HIV-associated lipodystrophy |
| Mechanism | MOTS-c activates AMPK by inhibiting the folate cycle, causing accumulation of AICAR (an AMP analog). Activated AMPK shifts cells into energy-efficient mode: enhancing glucose uptake, fatty-acid oxidation, and mitochondrial respiration while downregulating fat storage and gluconeogenesis. Under stres... | Tesamorelin binds to and stimulates human GRF (growth hormone-releasing factor) receptors on the anterior pituitary with similar potency as endogenous GRF, stimulating synthesis and release of endogenous growth hormone. This increases IGF-1 and IGFBP-3 levels, leading to increased lipolysis and redu... |
| Half-Life | Several hours; tissue effects may persist longer | ~26–38 minutes |
| Bioavailability | — | — |
| Molecular Weight | ~2174.6 g/mol | ~5135.9 g/mol |
| WADA Status | Not Listed | Prohibited |
| Research Half-Life | Several hours; tissue effects may persist longer | ~26–38 minutes |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | Not FDA-approved. Removed from FDA Category 2 on April 15, 2026. PCAC review scheduled July 23-24, 2026. Research chemical. | FDA-approved: Egrifta SV (Oct 2019) and Egrifta WR (March 2025) for HIV-associated lipodystrophy. Prescription only. |
Research Material Specifications
Catalog specifications for the corresponding research materials, including batch documentation coverage.
| Specification | MOTS-c | Tesamorelin |
|---|---|---|
| Purity Standard | ≥98% | ≥98% |
| CAS Number | 1627580-64-6 | 218949-48-5 |
| Molecular Formula | C₁₀₁H₁₅₂N₂₈O₂₂S₂ | C₂₂₃H₃₇₀N₇₂O₆₉S |
| Available Formats | 20mg, 10mg | 10mg, 20mg, 10mg |
| Batch COAs Published | — | — |
| Stock Status | In stock | In stock |
Availability at Volta Peptides
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.